Date published: 2026-5-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

0610006L08Rik Activators

0610006L08Rik Activators consist of a variety of chemical compounds that, through diverse signaling mechanisms, can enhance the functional activity of the0610006L08Rik Activators are a diverse array of chemical compounds that indirectly augment the functional activity of the protein 0610006L08Rik via multiple signaling pathways. Forskolin, through the activation of adenylate cyclase, increases intracellular cAMP, leading to activation of protein kinase A (PKA), which could phosphorylate substrates that interact with 0610006L08Rik, thereby enhancing its activity. Similarly, PMA activates protein kinase C (PKC), potentially affecting signaling pathways that include 0610006L08Rik as a component, while calcium ionophores like A23187 and Ionomycin elevate intracellular calcium levels, which may activate calcium-dependent pathways that involve 0610006L08Rik. IBMX and Rolipram both inhibit phosphodiesterases, maintaining elevated levels of cAMP and potentially enhancing 0610006L08Rik activity through cAMP-dependent signaling. Furthermore, sildenafil and zaprinast selectively inhibit PDE5 leading to increased cGMP levels, which could potentially interact with cGMP-dependent signaling pathways involving 0610006L08Rik.

The second set of 0610006L08Rik activators includes compounds that target different aspects of cellular signaling, potentially influencing 0610006L08Rik activity. Y-27632, a ROCK inhibitor, could modify actin cytoskeleton dynamics and possibly affect the function of 0610006L08Rik if it is associated with such processes. LY294002, by inhibiting PI3K, could alter AKT signaling pathways and thereby indirectly influence 0610006L08Rik activity. PD98059, a MEK inhibitor, while typically associated with inhibition of the MAPK/ERK pathway, could lead to a compensatory activation of alternative pathways that include 0610006L08Rik. Lastly, KN-93, which inhibits CaMKII, might enhance 0610006L08Rik by altering the balance of Ca2+/calmodulin-dependent processes. These chemicals, through their targeted effects on distinct cellular signaling mechanisms, have the potential to collectively amplify the biological functions of 0610006L08Rik, showcasing the intricate web of regulation within cellular signaling networks where 0610006L08Rik is a participant.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA, or phorbol 12-myristate 13-acetate, activates protein kinase C (PKC), which can lead to downstream effects that enhance the functional activity of "0610006L08Rik" if it is involved in PKC-mediated signaling pathways.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 acts as a calcium ionophore, increasing intracellular calcium levels, which can enhance "0610006L08Rik" activity by activating calcium-dependent proteins and pathways that interact with "0610006L08Rik".

Ionomycin

56092-82-1sc-3592
sc-3592A
1 mg
5 mg
$78.00
$270.00
80
(4)

Ionomycin, another calcium ionophore, raises intracellular calcium and could thereby enhance "0610006L08Rik" by similar mechanisms as A23187.

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX, a non-specific inhibitor of phosphodiesterases, prevents cAMP degradation, potentially enhancing signaling pathways that increase "0610006L08Rik" activity.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$186.00
$707.00
88
(1)

Y-27632 inhibits Rho-associated protein kinase (ROCK), potentially enhancing "0610006L08Rik" by altering actin cytoskeleton dynamics if "0610006L08Rik" is involved in such processes.

Rolipram

61413-54-5sc-3563
sc-3563A
5 mg
50 mg
$77.00
$216.00
18
(1)

Rolipram, a selective PDE4 inhibitor, raises cAMP levels, which could enhance the activity of "0610006L08Rik" through cAMP-dependent pathways.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

LY294002 inhibits PI3K, which can enhance "0610006L08Rik" activity by altering downstream AKT signaling if "0610006L08Rik" is linked to this pathway.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$40.00
$92.00
212
(2)

PD98059 is a MEK inhibitor, which can enhance "0610006L08Rik" by modulating the MAPK/ERK pathway if "0610006L08Rik" is regulated by this pathway.

KN-93

139298-40-1sc-202199
1 mg
$182.00
25
(1)

KN-93 is a selective inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), which could enhance "0610006L08Rik" if it is modulated by CaMKII-mediated signaling.

Zaprinast (M&B 22948)

37762-06-4sc-201206
sc-201206A
25 mg
100 mg
$105.00
$250.00
8
(2)

Zaprinast inhibits PDE5 like Sildenafil, potentially raising cGMP levels and enhancing "0610006L08Rik" activity if it plays a role in cGMP-mediated signaling.